$BPTH
BIO-PATH HOLDINGS, INC.

2016 Q3 Form 10-Q Financial Statement

#000114420416117698 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $680.0K $760.0K $590.0K
YoY Change 30.77% 33.33% -32.18%
% of Gross Profit
Research & Development $2.313M $1.190M $870.0K
YoY Change 133.17% 110.99% -46.64%
% of Gross Profit
Depreciation & Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.994M $1.944M $1.463M
YoY Change 98.02% 71.88% -8.74%
Operating Profit -$2.994M -$1.463M
YoY Change 98.02% -8.74%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $1.424M $2.000K $5.000K
YoY Change 35500.0% -60.0% -4.58%
Pretax Income -$1.570M -$1.940M -$1.460M
YoY Change 3.97% 71.68% -8.75%
Income Tax
% Of Pretax Income
Net Earnings -$1.570M -$1.942M -$1.458M
YoY Change 4.11% 72.47% -8.75%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.271M -$4.311M -$3.244M
COMMON SHARES
Basic Shares Outstanding 95.65M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.30M $4.220M $8.850M
YoY Change 14.72% -61.91% -36.15%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.110M $1.860M $179.0K
YoY Change 452.86% 95.79% 78.12%
Inventory
Prepaid Expenses $196.0K $560.0K
Receivables
Other Receivables
Total Short-Term Assets $12.41M $6.080M $9.593M
YoY Change 18.64% -49.46% -32.03%
LONG-TERM ASSETS
Property, Plant & Equipment $66.00K $51.00K $72.00K
YoY Change -19.78% -44.9% -36.35%
Goodwill
YoY Change
Intangibles $969.0K $1.010M $1.090M
YoY Change -14.28% -13.72% -12.86%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.030M $1.060M $1.162M
YoY Change -15.07% -16.05% -14.81%
TOTAL ASSETS
Total Short-Term Assets $12.41M $6.080M $9.593M
Total Long-Term Assets $1.030M $1.060M $1.162M
Total Assets $13.44M $7.140M $10.76M
YoY Change 15.14% -46.29% -30.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $120.0K $120.0K $54.00K
YoY Change -5.6% -68.84% 31.62%
Accrued Expenses $750.0K $690.0K $883.0K
YoY Change 111.8% 122.58% 248.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $870.0K $813.0K $937.0K
YoY Change 80.79% 17.83% 66.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.200M
YoY Change
Total Long-Term Liabilities $3.200M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $870.0K $813.0K $937.0K
Total Long-Term Liabilities $3.200M $0.00 $0.00
Total Liabilities $4.070M $813.0K $937.0K
YoY Change 745.75% 17.83% 66.73%
SHAREHOLDERS EQUITY
Retained Earnings -$29.19M -$25.38M
YoY Change 30.22% 27.45%
Common Stock $90.00K $90.00K
YoY Change 0.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.380M $6.327M $9.818M
YoY Change
Total Liabilities & Shareholders Equity $13.44M $7.140M $10.76M
YoY Change 15.14% -46.28% -30.51%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q4
OPERATING ACTIVITIES
Net Income -$1.570M -$1.942M -$1.458M
YoY Change 4.11% 72.47% -8.75%
Depreciation, Depletion And Amortization $50.00K $50.00K $50.00K
YoY Change 0.0% 0.0% 0.0%
Cash From Operating Activities -$1.910M -$2.250M -$1.000M
YoY Change 56.56% 64.23% -13.79%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.010M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.910M -2.250M -1.000M
Cash From Investing Activities -30.00K 0.000
Cash From Financing Activities 9.010M 0.000
Net Change In Cash 7.070M -2.250M -1.000M
YoY Change -679.51% 64.23% 29.87%
FREE CASH FLOW
Cash From Operating Activities -$1.910M -$2.250M -$1.000M
Capital Expenditures -$30.00K $0.00
Free Cash Flow -$1.880M -$1.000M
YoY Change 54.1% -9.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
813000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
937000 USD
CY2016Q2 us-gaap Liabilities
Liabilities
813000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
937000 USD
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
90000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
90000 USD
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35430000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
35112000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29193000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25384000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
6327000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
9818000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7140000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10755000 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1157000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1353000 USD
us-gaap Operating Expenses
OperatingExpenses
2510000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2510000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
10000 USD
us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-1942000 USD
us-gaap Depreciation
Depreciation
21000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
153000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
130000 USD
us-gaap Adjustment For Amortization
AdjustmentForAmortization
80000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2779000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-2779000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
184000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89763 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2207000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1606000 USD
us-gaap Operating Expenses
OperatingExpenses
3813000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3813000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3809000 USD
CY2015Q2 us-gaap Revenues
Revenues
0 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
564000 USD
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
567000 USD
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
1131000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1131000 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-1126000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89763 shares
CY2016Q2 us-gaap Revenues
Revenues
0 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
757000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 USD
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89763 shares
us-gaap Adjustment For Amortization
AdjustmentForAmortization
80000 USD
us-gaap Depreciation
Depreciation
21000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1097000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-124000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4630000 USD
us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-4630000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
318000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
541000 USD
CY2014Q4 us-gaap Cash
Cash
13859000 USD
CY2015Q2 us-gaap Cash
Cash
11080000 USD
CY2015Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
100000 USD
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5752000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1300000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7052000 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5345000 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.55
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.33
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5700000 USD
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
200000 USD
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2016Q2 bpth Drug Supplier Commitments Development
DrugSupplierCommitmentsDevelopment
100000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001133818
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
BPTH
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
95645224 shares
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72000 USD
CY2016Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1010000 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1090000 USD
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5882352 shares
CY2016Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0137 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0165 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.09 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.39 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure

Files In Submission

Name View Source Status
0001144204-16-117698-index-headers.html Edgar Link pending
0001144204-16-117698-index.html Edgar Link pending
0001144204-16-117698.txt Edgar Link pending
0001144204-16-117698-xbrl.zip Edgar Link pending
bpth-20160630.xml Edgar Link completed
bpth-20160630.xsd Edgar Link pending
bpth-20160630_cal.xml Edgar Link unprocessable
bpth-20160630_def.xml Edgar Link unprocessable
bpth-20160630_lab.xml Edgar Link unprocessable
bpth-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v445454_10q.htm Edgar Link pending
v445454_ex31.htm Edgar Link pending
v445454_ex32.htm Edgar Link pending
v445454_ex4-5.htm Edgar Link pending